 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| S-cibenzoline (CT-G20) / Celltrion
Trial termination: A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 in Subjects With Obstructive Hypertrophic Cardiomyopathy (clinicaltrials.gov) - Mar 2, 2023
P1, N=23, Terminated, Sponsor: Celltrion
Recruiting --> Terminated; The termination criteria of the protocol was met during dose escalation
- | S-cibenzoline (CT-G20) / Celltrion
Trial completion date, Trial primary completion date: A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 in Subjects With Obstructive Hypertrophic Cardiomyopathy (clinicaltrials.gov) - Aug 15, 2022
P1, N=24, Recruiting, Sponsor: Celltrion
Recruiting --> Terminated; The termination criteria of the protocol was met during dose escalation Trial completion date: Apr 2022 --> Sep 2022 | Trial primary completion date: Apr 2022 --> Sep 2022
- | S-cibenzoline (CT-G20) / Celltrion
Trial completion date, Trial primary completion date: A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 in Subjects With Obstructive Hypertrophic Cardiomyopathy (clinicaltrials.gov) - Mar 8, 2022
P1, N=24, Recruiting, Sponsor: Celltrion
Trial completion date: Apr 2022 --> Sep 2022 | Trial primary completion date: Apr 2022 --> Sep 2022 Trial completion date: Jan 2022 --> Apr 2022 | Trial primary completion date: Jan 2022 --> Apr 2022
- | S-cibenzoline (CT-G20) / Celltrion
Trial completion date, Trial primary completion date: A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 in Subjects With Obstructive Hypertrophic Cardiomyopathy (clinicaltrials.gov) - Oct 12, 2021
P1, N=24, Recruiting, Sponsor: Celltrion
Trial completion date: Jan 2022 --> Apr 2022 | Trial primary completion date: Jan 2022 --> Apr 2022 Trial completion date: Jun 2021 --> Jan 2022 | Trial primary completion date: Jun 2021 --> Jan 2022
- | S-cibenzoline (CT-G20) / Celltrion
Trial completion date, Trial primary completion date: A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 in Subjects With Obstructive Hypertrophic Cardiomyopathy (clinicaltrials.gov) - Feb 16, 2021
P1, N=24, Recruiting, Sponsor: Celltrion
Trial completion date: Jun 2021 --> Jan 2022 | Trial primary completion date: Jun 2021 --> Jan 2022 Trial completion date: Dec 2020 --> Jun 2021 | Trial primary completion date: Dec 2020 --> Jun 2021
- ||| S-cibenzoline (CT-G20) / Celltrion, CT-G11 / Celltrion
Trial completion: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 or CT-G11 and Food Effect of CT-G20 in Human Participants (clinicaltrials.gov) - Jun 9, 2020
P1, N=72, Completed, Sponsor: Celltrion
Trial completion date: Dec 2020 --> Jun 2021 | Trial primary completion date: Dec 2020 --> Jun 2021 Recruiting --> Completed
- || S-cibenzoline (CT-G20) / Celltrion
New P1 trial: A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 in Subjects With Obstructive Hypertrophic Cardiomyopathy (clinicaltrials.gov) - Jun 4, 2020
P1, N=24, Recruiting, Sponsor: Celltrion
- || S-cibenzoline (CT-G20) / Celltrion, CT-G11 / Celltrion
Enrollment change, Trial completion date, Trial primary completion date: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 or CT-G11 and Food Effect of CT-G20 in Human Participants (clinicaltrials.gov) - Mar 13, 2020
P1, N=72, Recruiting, Sponsor: Celltrion
Recruiting --> Completed N=48 --> 72 | Trial completion date: Jun 2019 --> May 2020 | Trial primary completion date: Jun 2019 --> May 2020
- || S-cibenzoline (CT-G20) / Celltrion, CT-G11 / Celltrion
New P1 trial: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 or CT-G11 and Food Effect of CT-G20 in Human Participants (clinicaltrials.gov) - Apr 18, 2019
P1, N=48, Recruiting, Sponsor: Celltrion